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Abstract: Skeletal aging is associated with reduced proliferative potential of bone marrow (BM)
multipotential stromal cells (MSCs). Recent data suggest the involvement of type 1 interferon (IFN1)
signalling in hematopoietic stem cell (HSC) senescence. Considering that BM-HSCs and BM-MSCs
share the same BM niche, we investigated IFN1 expression profile in human BM-MSCs in relation to
donor age, culture-expansion and IFN1 (α and β) stimulation. Fluorescence-activated cell sorting
was used to purify uncultured BM-MSCs from younger (19–41, n = 6) and older (59–89, n = 6) donors
based on the CD45lowCD271+ phenotype, and hematopoietic-lineage cells (BM-HLCs, CD45+CD271−)
were used as controls. Gene expression was analysed using integrated circuits arrays in sorted fractions
as well as cultured/stimulated BM-MSCs and Y201/Y202 immortalised cell lines. IFN1 stimulation
led to BM-MSC growth arrest and upregulation of many IFN1-stimulated genes (ISGs), with IFNβ
demonstrating stronger effects. Uncultured MSCs were characterised by a moderate-level ISG
expression similar to Y201 cells. Age-related changes in ISG expression were negligible in BM-MSCs
compared to BM-HLCs, and intracellular reactive oxygen species (ROS) levels in BM-MSCs did not
significantly correlate with donor age. Antiaging genes Klotho and SIRT6 correlated with more ISGs
in BM-MSCs than in BM-HLCs. In patients with osteoarthritis (OA), BM-MSCs expressed considerably
lower levels of several ISGs, indicating that their IFN1 signature is affected in a pathological condition.
In summary, BM-MSCs possess homeostatic IFN1 gene expression signature in health, which is
sensitive to in vitro culture and external IFN1 stimulation. IFN signalling may facilitate in vivo
BM-MSC responses to DNA damage and combating senescence and aberrant immune activation.
Keywords: aging; mesenchymal stromal cells; bone marrow; type 1 interferon; senescence
1. Introduction
Aging-associated health and well-being concerns have increased in the last two to three decades [1]
owing to the global demographic shift towards people aged over 60 [2]. While several hallmarks of
aging have been suggested as the underlying causes of age-related conditions [3], the exact mechanisms
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leading to deterioration of health at advanced age, including decline in immunity and increased frailty
are yet to be established.
Among the age-related diseases, those associated with the skeletal system are the leading
contributors of disability worldwide according to the World Health Organisation [4]. The skeletal
system forms the basic framework of the body, protecting internal organs and performing movements
and other mechanical and homeostatic functions. Certain bones also contain active bone marrow
(BM), which is the site of haematopoiesis, where various cell types are formed owing to the activity
of BM-resident hematopoietic stem cells (BM-HSCs) and multipotential stromal cells (BM-MSCs) [5].
With advancing age, the essential activities of both BM-HSCs and BM-MSCs appear to decline, resulting
in a phenomenon known as inflamm-aging and age-related bone loss [6]. Inflamm-aging conceptually
postulates an intrinsic decline of the proliferation potential and increase in senescence and DNA damage
in immune-lineage cells. This is accompanied by the reduction of protective extrinsic mechanisms
within the cellular microenvironment that aim at removal of senescent cells and accumulated damage,
that is, autophagy [7]. Among the most noted hallmarks of inflamm-aging is the preferential increase
in the myeloid lineage cell production, also known as “myeloid skewing” [8]. Age-related bone loss,
on the other hand, is associated with inefficient bone remodelling processes [9] and cell senescence,
mainly due to oxidative stress and DNA damage, as well as telomere erosion [10,11].
Considering that BM-MSCs locally participate in multiple cellular processes, including bone
formation and the control of bone remodelling, as well as BM-HSC support activity [12], understanding
age-related changes in BM-MSCs is of considerable importance. Recently, several studies have
documented an age-related decline in the number and particularly, colony sizes of human BM-MSCs,
identified using CD271 or SSEA4 marker expression [13–15]. Within these phenotypes, multipotential
BM-MSCs may be replaced with dysfunctional and presenescent stromal cells in aged individuals.
However, this process has not yet been documented formally in humans owing to the low frequencies
of BM-MSCs, as well as difficulties of in situ identification of senescent cells in bone [11].
In BM-HSCs, cell senescence triggered by oxidative stress and DNA damage is mediated via
the cytosolic DNA-sensing cGAS/STING pathway, which leads to an activation of cell-intrinsic type-1
interferon (IFN1) response [16,17]. Type-1 interferons (IFN1) bind to their receptor subunits IFNα 1
and 2 (IFNAR1 and IFNAR2) and signal using the Janus kinase and signal transducer and activation
of transcription (JAK-STAT) pathway. Initially described as innate immune cells’ response to viral
pathogens (extrinsic IFN1 response), homeostatic IFN1-stimulated gene (ISG) upregulation in other
cells, including BM-HSCs and other types of stem cells, have been more recently connected to a cell’s
control of autophagy, proliferation, apoptosis, and senescence (intrinsic IFN1 response) [16,18,19].
Interestingly, distinct IFN1 profiles of in-vitro-expanded BM-MSC clones have been recently linked to
MSC subpopulations with different proliferation, migration and immunomodulation capacities [20].
Furthermore, BM-MSC senescence in patients with systemic lupus erythematosus (SLE), an autoimmune
disease in which IFN1 is known to be produced in excess [21], has been found to be associated with
an upregulation of certain IFN1 ISGs [20,22,23]. Collectively, these data indicate a possibility of age-
and disease-related changes in IFN1 gene expression profiles of BM-MSCs; however, very little is
yet known about IFN1 expression signature in BM-MSCs in vivo or following standard expansion or
IFN1 stimulation.
Based on the fact that BM-MSC gene expression levels change significantly after in vitro
expansion [24,25], the aim of this study was to investigate intrinsic IFN1 gene expression profile
of human BM-MSCs and to explore any potential changes in this profile in relation to donor
age, culture-expansion or IFN1 stimulation. MSCs were purified using the commonly-accepted
CD45lowCD271+ phenotype [13,15] and their IFN1 gene expression was compared to donor matched
hematopoietic-lineage cells (BM-HLCs: CD45+CD271−) as well as cultured and interferon α-
and β-stimulated BM-MSCs. It was hypothesised that (1) BM-MSCs would be responding to IFN1
stimulation, (2) IFN1 gene expression would be different between uncultured and cultured BM-MSCs,
(3) the expression of certain ISGs could change in older donors MSCs due to increased DNA damage
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and (4) that IFN1 profiles of BM-MSCs would be different to BM-HLCs, reflecting their different
homeostatic functions within the BM. We also hypothesised that BM-MSC and BM-HLC IFN1 gene
expression profiles could be altered in osteoarthritis (OA), a disease characterised by aberrant local
and systemic immune responses [26,27].
2. Materials and Methods
2.1. Patients and Cells
Bone marrow aspirate (BMA) was collected from 15 donors undergoing fracture correction
or removal of metal work that were otherwise healthy. Cells from 12 donors (n = 6 young,
range 19–40 years old and n = 6 old, range 59–89 years old) based on age groups boundaries
defined earlier [15] were used for cell sorting and native BM-MSC IFN1 profile evaluation. Cells from
three donors (aged 23, 49 and 59 years old) were used for IFN1 stimulation experiments. For the OA part
of the study, BM-MSCs were extracted from femoral heads of seven patients (age range 56–82 years old),
as previously described [28,29], and their BM-MSC IFN1 gene expression profiles were compared with
older healthy donors (n = 6, range 59–89 years old). The ethical approval for the study was provided
by the Yorkshire and Humberside National Research Ethics Committee (reference 06/Q1206/127,
11 April 2012) and the Yorkshire & The Humber—South Yorkshire Research Ethics Committee
(reference 14/YH/0087, 17 July 2014). Written informed consent was obtained from all patients.
2.2. Sample Processing and Cell Sorting
An average of 8 mL of BMA was collected in ethylenediaminetetraacetic acid (EDTA) tubes
and filtered through 70 µm cell strainer (Thermo Fisher Scientific, Warrington, UK)) to remove any
cellular clumps. Next, the red blood cells were lysed using 1:9 BMA: ammonium chloride (v/v) by
incubation at 37 ◦C for 5 min. The BMA and ammonium chloride mix was then centrifuged at 300× g
for 10 min at room temperature (RT) and the obtained cell pellet was further washed twice with
phosphate buffer saline (PBS) (Thermo Fisher Scientific) to eliminate traces of remaining ammonium
chloride. Following counting, the cell suspension was centrifuged at 300× g for 10 min at RT and frozen
in DMEM with 45% foetal bovine serum (FBS) and 10% dimethylsulfoxide (DMSO). The frozen samples
were defrosted, washed with PBS to remove any traces of DMSO and then enriched with anti-fibroblast
magnetic beads (Miltenyi Biotec, Bergisch Gladbach, Germany) as previously described [24] and then
subjected to cell sorting to separate BM-MSCs (CD45lowCD271+) and BM-HLCs (CD45highCD271−)
cells, as previously described [15]. In brief, enriched cells were stained with the following antibodies
for 15 min: 20 µL CD45 V450 and 20µL CD271 PE Vio770 (both from BD Pharmingen, Oxford, UK)
and 10 µL of 7-AAD (BD Pharmigen) was added to the cells immediately prior to cell sorting, which
was performed using a BD Influx cell sorter [15]. For each antibody, isotype controls were used to
control for nonspecific antibody binding. Sorted cells of the following populations CD45lowCD271+
(BM-MSCs) and CD45highCD271− (BM-HLCs) were collected into 1.5 mL Eppendorf tubes containing
350 µL guanidinium-based lysis buffer (Buffer RL, Norgen Biotek, Thorold, Canada), and lysates
were frozen at −80 ◦C for subsequent RNA extraction and qPCR. The number of BM-MSCs collected
after sorting was in the range of 647 to 22,2229 cells (median of 4694 cells), whereas the number of
BM-HLCs collected was always 70,000 cells The expression of 102 genes (Supplementary Table S1)
was investigated in both the populations. Multipotential BM-MSC genes were investigated for potential
changes in differentiation and proliferation in Flex sixTM IFC, whereas, IFN1 genes were investigated
in 48.48.gene IFCTM (both Fluidigm, San Francisco, California, USA).
2.3. Quantitative Polymerase Chain Reaction (qPCR)
RNA was extracted from cell lysates obtained from cell sorting described in [15] using Single Cell
RNA Purification Kit (Norgen Biotek) following manufacturer instructions with genomic DNA removal
using DNAse I from the same company. The eluted RNA was reverse transcribed, preamplified
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for 18 cycles using Fluidigm reagents as per the outlined manufacturer protocols. Quantitative
PCR (qPCR) was then performed using 48.48 Dynamic Array™ IFC on BioMark HD. The Ct
values for genes of interest were normalised to the endogenous control HPRT-1 using the formula
∆Ct = Cttarget gene − Cthousekeeping gene and relative expression was calculated as 2−∆Ct and used for
statistical analysis. The Cluster and Treeview softwares were used to generate clusters of gene
expression data for visualisation of heatmaps across donor cells and stimulations. The clusters are
presented by the level of expression of genes, highest indicated in red (+ 3) to lowest indicated in
green (−3). The grey squares indicate data points that were below detection level.
2.4. BM-MSC Culture and IFN1 Stimulation
Y201 and Y202 immortalised BM-MSC cell lines [20] as well as primary BM-MSCs from
unsorted BM were cultured in StemMacs MSC expansion media (Miltenyi Biotec) containing 1%
(v/v) penicillin streptomycin (PS) for three passages prior to stimulation or gene expression study,
as previously described. Twenty-four hours prior to IFN1 stimulation, cells were seeded in duplicate
wells of six-well plates at a density of 25,000 cells per well in 1 mL of expansion media. The following
day, media was removed and cells were stimulated with 2 mL expansion media containing varying
concentrations of IFNα or β (STEMCELL technologies Vancouver, Canada and Pepro Tech, London, UK,
respectively) for up to 3 days (Supplementary Figure S1). Based on BST2 gene expression, 10 ng/mL
concentration was selected for subsequent experiments and cells were cultured for up to 7 days.
Control wells containing only expansion media were prepared in duplicate for all time points. Cells
to be harvested on day 7 underwent a half media change with the same media on day 3. Cells were
harvested on days 3 and 7 days post stimulation to assess both proliferation and gene expression.
Gene panel used for this part of the study is shown in Supplementary Table S2.
On the day of harvesting, stimulation media was removed, wells were washed with 1 mL
Dulbecco’s Phosphate Buffered Saline (DPBS) twice and cells harvested using Trypsin/EDTA (both from
Sigma, Poole, UK). The effects of IFNα or β on BM-MSC proliferation were assessed via cell counting
and confirmed, in selected experiments, by DNA quantification. After counting, all cells were lysed for
RNA extraction and gene expression evaluation, as explained in the section above.
2.5. Intracellular ROS Measurements
BMA samples from young (n = 7) and old donors (n = 6) were treated with ammonium chloride
to attain red cell lysis and washed with PBS. A total of 2 × 106 cells were added to two flow cytometry
tubes. The cells in the first tube were left as it is (to measure basal ROS) and the second tube
was treated with tertbutyl hydrogen peroxide (Thermo Fisher Scientific) to generate induced ROS,
as described previously [30], and was used as a positive control for the assay. Both the tubes were
placed in the incubator for an hour, washed with PBS and then stained with 20 µL CD45 V450, 20 µL CD
271 PE-Vio770, and 2 µL CellROX FITC (Thermo Fisher Scientific) for 15 min and washed. CellROX is a
nonfluorescent dye under reduced state, which upon oxidation, exhibits fluorescence. After incubation,
the cells were washed in PBS, the supernatant was discarded and the cells were resuspended in 100 µL
of medium (DMEM + 10%FBS). Finally, 2 µL SYTOX APC (Thermo Fisher Scientific) was added to
distinguish between live and dead cells for 15 min. The cells were then analysed for the production of
intracellular ROS using flow cytometry (LSRII, BD Pharmigen) following gating on live CD45lowCD271+
BM-MSCs, and the data was analysed using FACS Diva version 8 (BD Pharmigen).
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2.6. Statistics
Statistical analysis and graphics were performed using GraphPad Prism software (version 7.0a,
San Diego, California, US). The normal distribution of the data was assessed using the Shapiro–Wilk
and Kolmogorov–Smirnov tests for normality. For data found not to be normally distributed,
the Mann–Whitney test was used for unpaired data and Wilcoxon-signed rank test for paired data.
Statistical analysis of BM-MSC stimulation data across three time points (day 0/day 3/day 7) was carried
out using one-way ANOVA followed by Kruskal–Wallis nonparametric test with Dunn correction for
multiple groups. The results were considered significant at p value of <0.05.
3. Results
3.1. IFN1 Profile and Reduced Proliferation of Cultured BM-MSCs upon IFN1 Stimulation
Different IFN1 profiles with upregulation of certain ISGs have been previously linked to stem cell
quiescence, senescence and proliferation [18,23,31]. To address our first aim and explore any differences
in IFN1 gene expression profile between unstimulated and stimulated BM-MSCs, primary cultured
BM-MSCs were treated with 10 ng/mL IFNα or IFNβ and their growth kinetics and IFN1 profiles
were compared (Figure 1). Reduction in BM-MSC proliferation was observed following stimulation
with either IFNα or IFNβ, consistent with early reports [32,33], and was statistically significant for
IFNβ on day 7. In the absence of IFN1 treatment, BM-MSCs continued to proliferate and increased
in numbers 3.4- and 6.6-fold on days 3 and 7, compared to day 0, respectively. The inhibitory effect of
IFNβ was more pronounced than IFNα and induced a complete growth arrest of BM-MSCs (Figure 1a).
BM-MSCs from the oldest donor (59 years old) displayed the slowest proliferation rate and were more
inhibited by IFNα (stopped proliferating on day 3) compared to younger donors (23 and 49 years old).
Similar to primary BM-MSCs, clonal cell lines Y201 and Y202 responded well to IFN1 stimulation and,
similarly, their growth was more inhibited by IFNβ than by IFNα (Supplementary Figure S1).
Cluster analysis of topical IFN1 transcripts revealed the presence of two clusters (clusters 1 and 2)
of genes (Figure 1b). Cluster 1 included transcripts for type I interferons (IFNα and IFNβ), their
receptors IFNAR1 and IFNAR2, and the intermediate signalling molecule STAT1 [34]. These genes
were expressed at a higher level in unstimulated, proliferating BM-MSCs compared in IFNα or IFNβ
stimulated BM-MSCs, regardless of the day of culture. This suggested a suppression of IFN signalling
and autocrine IFN production in the presence of external IFNs. Cluster 2 contained large numbers of
ISGs, including BST2 and Mx1, that were previously shown to be expressed in native and cultured
BM-MSCs (Figure 1b) [20,35]. Interestingly, within the stimulated samples, those treated with IFNβ
showed a more distinct separation from unstimulated BM-MSCs, compared to BM-MSCs stimulated
with IFNα, suggesting that gene expression of a majority selected ISGs was more strongly induced
by IFNβ than IFNα (i.e., HERC5 and ISG20) (Figure 1b). Time-course expression of a representative
Cluster 2 transcript USP18 on BM-MSCs from three individual donors, as well as control cell lines
Y201 and Y202, is shown on Figure 1c. These data revealed clear differences in IFN1 gene expression
profiles between cultured, proliferating BM-MSCs and IFN1-stimulated, growth inhibited BM-MSCs.
Based on gene clustering, donor age appeared to have a lesser effect on ISG expression in BM-MSCs
compared to IFN1 type or treatment duration (3 or 7 days).
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upregulated following IFN1 stimulation, respectively. The colour key on the right indicates the range 
of expression levels with highest expression red and lowest in green. Grey squares indicate data 
points that were below detection. (c) Time-course expression of a representative Cluster 2 transcript 
USP18 on BM-MSCs from three individual donors and control cell lines Y201 and Y202. 
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Figure 1. Growth and IFN1 profile changes in cultured bone marrow multipotential stromal cells
(BM-MSCs) following IFNα or β stimulation. (a) Reduced proliferation in BM-MSC cultures upon
exposure to IFNα or β. Three-way analysis of variance (ANOVA) followed by Kruskal–Wallis test,
** p < 0.01, n = 3 donors, symbols represent means, error bars indicate ± standard error of the mean
(SEM). (b) IFN1 profile in BM-MSCs without and with IFNα or β stimulation. Cluster analysis
of BM-MSC gene expression (n = 3 donors, label numbers indicate donor ages). Dendograms on
the top indicate samples’ clustering: the symbols “α” and “β” indicate treatment with IFNα and IFNβ,
respectively, and “c” indicates control nonstimulated samples. Cluster 1 and 2 indicate transcripts
down- and upregulated following IFN1 stimulation, respectively. The colour key on the right indicates
the range of expression levels with highest expression red and lowest in green. Grey squares indicate
data points that were below detection. (c) Time-course expression of a representative Cluster 2 transcript
USP18 on BM- SCs from three individual donors and control cell lines 201 and Y202.
3.2. IFN1 Profile of Uncultured CD45lowCD271+ BM-MSCs in Comparison to Cultured and IFN1
Stimulated BM-MSCs
As documented in previous independent studies, standard BM-MSC culture expansion leads to
downregulation in the expression of a large number of genes, including ISGs [24,25,36]. To get insights
into the in vivo IFN1 “status” of uncultured BM-MSCs, the IFN1 profile of purified CD45lowCD271+
cells was first compared to standard cultured BM-MSCs (nonstimulated, Figure 2). The analysis
subsequently included BM-MSCs cultured in the presence of IFNα or IFNβ, as well as immortalised
BM-MSCs cell lines Y201 (differentiation competent) and Y202 (immunomodulatory) previously shown
to radically differ in their IFN1 and ISG profiles [20] (Figure 3).
Cluster analysis of the 30 selected genes in purified and culture expanded BM-MSCs revealed
distinct segregation of purified native BM-MSCs (labelled as CD271+) from the cultured BM-MSCs,
whereas the effects of donor age were less apparent (Figure 2). The expression of interferons (IFNα
and IFNβ), as well as several well-known ISGs, including Mx1, HERC5, IFITM1, BST2, and IRF7,
were distinctly downregulated following culture (Cluster 1, Figure 2). In contrast, another distinct
cluster contained genes that were upregulated in culture, included IFN receptors genes (IFNAR1
and IFNAR2), STAT1, ISG20, as well as BID and MITCH that connect DNA-damage-associated
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IFN1 signalling with reactive oxygen species (ROS) accumulation and cell senescence [37]. Higher
levels of autocrine IFN1 transcription and lower levels of IFN receptors’ transcription in uncultured
BM-MSCs suggested that the in vivo BM-MSC niche may be relatively rich in IFN1 compared to
in vitro conditions.
A broader view, with the inclusion of IFNα or IFNβ stimulated BM-MSCs as well as Y201
and Y202 BM-MSC cell lines, revealed further interesting findings. Firstly, uncultured/purified
BM-MSCs and cultured BM-MSCs were clearly segregated from IFN1-stimulated BM-MSCs and were
more similar to each other than to stimulated BM-MSCs (Figure 3). Secondly, Y201 data clustered
nearer to cultured BM-MSCs, while most Y202 data clustered clearly with stimulated BM-MSCs.
This was reassuring as Y202 cells were originally described as clonally expanded BM-MSCs with a
more prominent IFN1 profile than Y201 cells [20]. Thirdly, a cluster of genes was identified that had
similar levels of expression in uncultured and stimulated BM-MSCs. The genes within this cluster
included OAS3 and BST2 previously described as associated with human BM-MSCs [20,35,38], as well
as IFITM3 and RTP4 (Cluster 1, Figure 3).Biomedicines 2019, 7, x FOR PEER REVIEW 9 of 25 
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Figure 2. Cluster analysis of uncultured and cultured BM-MSCs. Uncultured BM-MSCs were purified
based on the CD45lowC + phenotype (n = 12 donors) and cultured BM-MSCs were harvested
from control wells with no stimulations on days 0, 3 and 7 of culture (n = 3 donors, label numbers
indicate donor ag s). Dendrograms n the top indicate the samples: CD271+—uncultured BM-MSCs,
MSC—cultured BM-MSCs, day 0 BM-MSC samples were performed in duplicate. Clusters 1 and 2
indicate transcripts down- and upregulated following culture, respectively. The colour key on the right
indicates the range of expression levels with highest expression red and lowest in green. Grey squares
indicate data points that were below detection.
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Cell type specificity in IFN1 profiles have been previously reported for immune-lineage cells 
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Figure 3. Cluster analysis of uncultured, cultured and IFNα- or IFNβ-stimulated BM-MSCs
and BM-MSC cell lines Y201 and Y202 without or with IFNα or β stimulation. Uncultured BM-MSCs
were purified based on the CD45lowCD271+ phenotype (n = 12 donors), and cultured BM-MSCs
were harvested from control wells with no stimulation on days 0, 3 and 7 of culture (n = 3 donors,
label numbers indicate donor ages). Dendograms on the top indicate the samples: CD271+—uncultured
BM-MSCs, MSC—cultured BM-MSCs, Y201/Y202—cell lines, α—stimulated with IFNα, β—stimulated
with IFNβ. Cluster 1 indicates transcripts expressed at similar levels in uncultured and IFN1-stimulated
BM-MSCs. The colour key on the right indicates the range of expression levels with highest expression
red and lowest in green. Grey squares indicate data points that were below detection.
3.3. Intrinsic IFN1 Profile of Uncultured CD45lowCD271+ BM-MSCs in Comparison to Control
CD45+CD271− BM-HLCs
Cell type specificity in IFN1 profiles have been previously reported for immune-lineage cells [39]
and different types of stem cells [18]. To investigate if IFN1 profile specificity exists in different-lineage
cells inhabiting the same BM environment, IFN1 gene expression in CD45lowCD271+ BM-MSCs
was next compared to CD45+CD271− BM-HLCs. Given only minor age-related differences observed so
far, the comparison was first performed for the whole donor cohort (n = 12, age range 19–89 years old)
and additional genes included molecules linked to the IFN1 > BID > ROS pathway, connecting
IFN1 signalling and cellular senescence (BID and MTCH2) [17,40], two topical antiaging genes
(KL and SIRT6) [41] and two genes indicating senescence-activated secretory phenotype (SASP)
(IL6 and IL8) [31].
Despite the fact that the majority of ISGs were previously shown to be expressed in immune
cells [35], and were therefore expected to have increased expression in BM-HLCs, the opposite was found
here, whereby a larger number of ISGs displayed significantly higher expression in BM-MSCs (Table 1).
For example, BM-MSCs expressed higher levels of transcripts for both IFN1 type receptors IFNAR1
and IFNAR2, transmembrane antiviral effectors IFITM1 and IFITM3, recently suggested to be important
in stem cell differentiation [18], as well as BST2, USP18, and KL (Figure 4a).
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Table 1. IFN1-stimulated genes (ISGs) and senescence-activated secretory phenotype (SASP)/senescence-related transcripts differentially-expressed between bone
marrow multipotential stromal cells (BM-MSCs, CD45lowCD271+ cells) and hematopoietic-lineage cells (BM-HLCs; CD45+CD271− cells).
Gene Name Gene Id MSC (Median) HLC (Median) Fold Difference p Value
SERPING Serine protease inhibitor, clade G (C1 inhibitor), member 1 22 0.094 233.3 0.0003
IFI27 Interferon gamma-inducible protein 27 1.551 0.01 155.1 <0.0001
PRDM16 PR domain containing 16 0.179 0.002 105.3 0.042
IL7 Interleukin 7 1.481 0.016 93.7 0.0005
CEACAM Carcinoembryonic antigen-related cell adhesion molecule 1 0.31 0.007 44.3 0.0021
IFITM3 Interferon induced transmembrane protein 3 137.9 3.79 36.4 <0.0001
KL Klotho 0.51 0.02 25.5 0.0083
USP18 Ubiquitin specific peptidase 18 0.35 0.02 17.5 <0.0001
LRP1 LDL Receptor Related Protein 1 48.92 4.03 12.1 0.0007
RTP4 Receptor (chemosensory) transporter protein 4 0.96 0.08 12 0.0036
IFITM1 Interferon induced transmembrane protein 1 75.05 6.33 11.9 0.0005
LY6E Lymphocyte antigen 6 complex, locus E 24.58 2.4 10.2 <0.0001
SPATS2L Spermatogenesis associated, serine-rich 2-like 3.509 0.405 8.7 0.0001
IFI6 Interferon inducible alpha protein 6 3.285 0.438 7.5 0.0145
IFIT5 Interferon induced protein with tetratricopeptide repeats 5 0.633 0.11 5.8 0.0284
CCND2 CyclinD2 2.359 0.415 5.7 0.0013
SOCS1 Suppressor of cytokine signalling 3 2.558 0.461 5.6 0.0003
ABCA1 ATP Binding Cassette Subfamily A Member 1 1.173 0.24 4.9 0.0249
IFNAR1 Interferon alpha receptor 1 4.28 0.88 4.9 0.0018
IFI44L Interferon induced protein 44 like 1.507 0.31 4.9 0.008
OASL 2′-5′-oligoadenylate synthetase 1.014 0.22 4.6 0.0284
PLSCR1 Phospholipid scramblase 1 4.117 0.998 4.1 0.0068
EIF2AK2 Eukaryotic translation initiation factor 2-alpha kinase 2 3.807 0.956 4 0.0023
OAS3 2′-5′-oligoadenylate synthetase 3 2.55 0.7 3.6 0.0121
IFI35 Interferon inducible alpha protein 35 2.68 0.76 3.5 0.0387
NT5C3B 5′-nucleotidase cytosolic IIIB 0.56 0.159 3.5 0.0018
RSAD2 Radical S-adenosyl methionine domain containing 2 0.434 0.132 3.3 0.0169
IFNAR2 Interferon alpha receptor 2 5.82 1.84 3.2 0.0332
IFI44 Interferon inducible alpha protein 44 3.1 1.01 3.1 0.0205
EPSTI1 Epithelial stromal interaction 1 1.59 0.57 2.8 0.0045
IFIH1 Interferon induced with helicase C domain 1 0.45 0.17 2.7 0.0106
UBE2L6 Ubiquitin/ISG15-conjugating enzyme E2 L6 11.86 4.5 2.6 0.0083
SAMD9L Sterile alpha motif domain containing 9-like 1.67 0.642 2.6 0.0387
BST2 Bone marrow stromal antigen 2, Tetherin (CD317) 12.06 4.97 2.4 0.0083
IFI16 Interferon inducible alpha protein 16 1.664 0.809 2.1 0.0068
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Table 1. Cont.
Gene Name Gene Id MSC (Median) HLC (Median) Fold Difference p Value
RGS1 Regulator of G protein signalling 1 0.621 32.29 52 0.0184
IL8 Interleukin 8 2.919 67.21 23 0.0022
TNF Tumour necrosis factor 0.17 3.67 21.6 0.013
IRF5 Interferon regulatory factor 5 0.129 1.285 10 0.0157
HPSE Heparanase 0.097 0.732 7.6 0.0171
FCGR1B Fc fragment of IgG receptor 1B 0.19 1.04 5.5 0.0031
BID BH3 interacting domain 0.21 1 4.8 0.0188
PRDM1 PR domain containing 1 0.51 1.72 3.4 0.0148
LAIR1 Leukocyte associated immunoglobulin like receptor1 0.43 1.4 3.3 0.0278
CASP1 Caspase1 3.06 6.16 2 0.0205
Gene expression was normalised to housekeeping gene HPRT1. The upper section of the table includes genes that were expressed significantly higher in MSCs than in HLCs, and the lower
section of the table includes genes that were expressed significantly higher in HLCs than in MSCs.
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0.002). 
Conversely, BM-HLCs were characterised by higher-level expression of IL8, as well as BID, a 
proapoptotic molecule that regulates mitochondrial ROS in the DDR-induced senescence induction 
pathway in BM-HSCs (Table 1 and Figure 4a) [64]. The expression of SIRT6 was higher in BM-MSCs 
in most donors, but the differences failed to reach statistical significance (Figure 4a). These data 
revealed distinct differences in IFN1 profiles in stromal and hematopoietic-lineage cells inhabiting 
the same BM environment. 
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seven panels) or BM-HLCs (last three panels). Wilcoxon-signed rank test for matched paired data, *p 
< 0.05, **p < 0.01 and ***p < 0.001, ns—nonsignificant. (b) Correlation of the expression of BM stroma-
producing cytokines IL7 and CXCL12 with the expression of IFITM1 and IFITM3 in uncultured BM-
MSCs. Spearman rank correlation test, IFITM1—dark symbols, IFITM3—light symbols. 
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BM-HLCs (CD45+CD271− cells). (a) Expression of genes that were higher expressed in BM-MSCs
(first seven panels) or BM-HLCs (last three panels). Wilcoxon-signed rank test for matched paired data,
* p < 0.05, ** p < 0.01 and *** p < 0.001, ns—nonsignificant. (b) Correlation of the expression of BM
stroma-producing cytokines IL7 and CXCL12 with the expression of IFITM1 and IFITM3 in uncultured
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As IFN1 signalling may be directly implicated in lineage-commitment or trophic functions of
BM-MSCs [18], the relationships between the expression of key BM-MSC lineage transcripts (FABP4,
PPARγ for adipogenesis, RUNX2, SPARC for osteogenesis and SOX9, ACN for chondrogenesis) were
next correl te with their xpression of IFN1 receptors or ISGs and no significant correlations were
found (data not shown). Contrastingly, he expression of IL7, a well-known BM stromal cytokine
i volved in lymphoid progenitor d velopment and B and T memory cells retention in the BM [42,43]
strongly positively correlated with many ISGs including highly-expressed IFITM1 and IFITM3
(Figure 4b). Howeve , the latter ISGs did not correlate with the transcript levels for another BM-MSC
stromal-support molecule CXCL12, which is involved in the BM-MSC support for the maintenance of
BM-HSCs [12,44] (Figure 4b). Interestingly, the expression of TNFSF11 (RANKL), a molecule promoting
bone resorption [45], had significant negative correlation with four other ISGs: Ly6E (r = −0.7692,
p = 0.005), LRP1 (p = −0.7273, p = 0.01), BST2 (r = −0.762, p = 0.01) and OAS3 (r = −0.8252, p = 0.002).
Conversely, BM-HLCs were characterised by higher-level expression of IL8, as well as BID,
a proapoptotic molecule that regulates mitochondrial ROS in the DDR-induced senescence induction
pathway in BM-HSCs (Table 1 and Figure 4a) [46]. The expression of SIRT6 was higher in BM-MSCs
in most donors, but the differences failed to reach statistical significance (Figure 4a). These data
revealed distinct differences in IFN1 profiles in stromal and hematopoietic-lineage cells inhabiting
the same BM environment.
3.4. Age-Related Changes in IFN1 Profile of CD45lowCD271+ BM-MSCs Compared to
CD45+CD271− BM-HLCs
Compared to younger donors’ BM-HLCs (19–40 years old), a number of genes displayed statistically
significant, over 2-fold reduction in older donors’ (59–89 years old) BM-HLCs (Table 2). In contrast,
only one gene RNF213 encoding ring finger protein 213 was reduced (p = 0.0411) in older donor
BM-MSCs. Notably, the expression of TMEM173 encoding STING, an adaptor molecule mediating
the cell’s responses to cytosolic DNA [47], as well as MTCH2, were significantly reduced in older
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donor BM-HLCs (p = 0.0152) (Table 2), which could, in theory, influence their cytoplasmic nucleic acid
sensing and intracellular ROS accumulation, respectively. The expression of KL encoding an antiaging
protein Klotho and IFN1 receptor IFNAR1 were also >2-fold reduced in old-donor BM-HLCs, albeit not
significantly. As expected, age-related changes in BM-MSCs or BM-HLCs were lower in magnitude
(maximum 5-fold for IL7R in HLCs) compared to cell type-specific differences between BM-MSCs
and BM-HLCs where over 50-fold differences were commonly found (Table 1). Individual’s biological
age does not always perfectly match their chronological age [48]. For this reason, the expression
of two antiaging molecules KL and SIRT6 was next correlated with a number of ISGs in both CD4
lowCD271+ BM-MSCs and CD45+CD271− BM-HLCs (Figure 5). Significant, strong positive correlations
between KL and RTP4 and KL and SIRT6 were found in both BM-MSCs (r = 0.9455, p = 0.001 for
RTP4 and r = 0.7182, p = 0.02 for SIRT) and BM-HLCs (r = 0.8364, p = 0.005 for RTP4 and r = 0.8,
p = 0.005 for SIRT6), but only in BM-MSCs did KL additionally correlate with IRF3 (r = 0.9, p = 0.001),
OAS3 (r = 0.7545, p = 0.02), CCND2 (r = 0.8909, p = 0.001) and BST2 (r = 0.8626, p = 0.002) (Figure 5a).
A similar pattern was found for SIRT6 although a number of coregulated genes was higher and included
IFNAR2, IRF9, IFI35, RNF213, RTP4 and KL; nevertheless, only in BM-MSCs did SIRT6 additionally
correlate with BST2 (r = 0.8636, p = 0.002), OAS3 (r = 0.8273, p = 0.002), IRF3 (r = 0.8364, p = 0.005)
and CCND2 (r = 0.7182, p = 0.02) (Figure 5b). In addition to our data showing an age-related
TMEM173/STING downregulation in BM-HLCs, but not in BM-MSCs, these data pointed towards
a potentially heightened state of readiness for DDR-related nucleic acid sensing and combating
senescence in BM-MSCs compared to BM-HLCs. To explore this possibility, we measured intracellular
ROS levels in CD45lowCD271+ BM-MSCs from 13 donors (aged 25–89 years old). While no notable
increases in basal ROS in BM-MSCs from older-aged donors were found (Figure 5c), interesting
trends for positive correlations were observed between basal ROS and the expression levels of both
TMEM173/STING and MTCH2 in BM-MSCs (Figure 5d), providing initial support for this idea.
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Figure 5. Venn diagrams showing expression of antiaging genes in correlation with ISGs in uncultured
BM-MSCs (CD45lowCD271+ cells) and control BM-HLCs (CD45+CD271− cells) and reactive oxygen
species (ROS) production in uncultured BM-MSCs in relationship to donor age and TMEM173/STING
and MTCH2 expression levels. (a) ISGs significantly correlating with KL and (b) ISGs significantly
correlating with Sirt6, in BM-MSCs, BM-HLCs and both types of cells. (c) Basal intracellular ROS levels
in uncultured BM-MSCs (CD45lowCD271+ cells) from 13 healthy donors. (d) Positive relationships
between basal ROS levels in uncultured BM-MSCs (CD45lowCD271+ cells) and their expression of
TMEM173/STING (left) and MTCH2 (right).
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Table 2. Age-related increase in expression of ISGs in BM-HLCs (CD45+CD271− cells).
Gene ID Gene Name Young (Median) Old (Median) Fold Difference p Value
IL7R Interleukin7 receptor 0.491 0.098 5.01 0.026
PRKRA Protein Kinase, Interferon-Inducible Double Stranded RNADependent Activator 0.970 0.200 4.85 0.0152
SCARB1 Scavenger Receptor Class B Member 1 0.431 0.131 3.29 0.0087
CXCL10 C-X-C motif chemokine 10 0.580 0.180 3.22 0.0667
RTP4 Receptor transporter protein 4 0.150 0.050 3.00 0.0152
CEACAM Carcinoembryonic antigen-related cell adhesion molecule 1 0.008 0.003 2.67 0.0667
Tp53 Tumour protein 53 2.930 1.210 2.42 0.0043
IRF9 Interferon regulatory factor 9 1.520 0.628 2.42 0.026
IRF3 Interferon regulatory factor 3 1.561 0.660 2.37 0.0411
ABCG1 ATP Binding Cassette Subfamily G Member 1 0.070 0.030 2.33 0.0649
TMEM173/STING Transmembrane protein 173/Stimulator of interferon genes 2.293 1.033 2.22 0.026
IFIT5 Interferon induced protein with tetratricopeptide repeats 5 0.124 0.058 2.14 0.0411
MTCH2 Mitochondrial carrier homolog 2 1.610 0.790 2.04 0.0152
Gene expression was normalised to housekeeping gene HPRT1. Table includes genes that were expressed significantly higher in BM-HLCs form older donors, indicating an age-related
increase in these ISGs in vivo.
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3.5. Differences in IFN1 Profile of CD45lowCD271+ BM-MSCs and CD45+CD271− BM-HLCs in Patients
with Osteoarthritis (OA)
To investigate how IFN1 gene expression in BM-MSCs may change in a pathological condition,
we next compared the IFN1 signature in native CD45lowCD271+ BM-MSCs from healthy older
subjects (age range 59–89 years old) with age-matched patients with osteoarthritis (OA) (age range
56–82 years old). To explore cell-specificity of these changes, the IFN1 signature in CD45+CD271−
BM-HLCs was also compared (Figure 6).
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Figure 6. Relative expression of selected IFN signature genes in both cell types (left panel: BM-MSCs,
right panel: BM-HLCs) in healthy old donors (n = 6) and age-matched OA patients (n = 7).
Data is represented as medians and error bars indicate interquartile rages. * p < 0.05 and ** p < 0.01,
Mann–Whitney U-test. All genes except IL7 present statistically significant reduction in BM-MSCs from
osteoarthritis (OA) patients compared to healthy old donors. BM-HLCs present a different pattern,
with IFI27 being significantly upregulated in OA.
As seen in this figure, prominent, statistically significant downregulation in several ISGs
was observed in BM-MSCs, which was clearly BM-MSC-specific as similar-level changes were not
evident in B -HLCs. IL7 expression was reduced (albeit nonsignificantly) in OA BM-MSCs in parallel
to IFITM1 and IFITM3 (Figure 6), consistent with data on the correlation between these transcripts
in healthy BM- SCs (Figure 4b). On the other hand, IL6 expression was induced in both OA BM-MSCs
and BM-HLCs, consist nt with pr vious stu ies on the overall increase in IL6 production in OA [49].
The full list of genes differentially expressed betw en OA BM-MSCs and OA BM-HLCs is provided
in Tab e 3.
Table 3. Differentially expressed IRGs in OA.
Gene ID Gene Name MSC (Median) HLC (Median) Fold Difference p Value
PRDM16 PR domain containing 16 0.11 0.001 110 0.055
SERPING Serine protease inhibitor, clade G (C1 inhibitor),member 1 8.8 0.086 102.3 0.0006
Kl Klotho 0.1 0.002 50 0.0175
LRP1 LDL Receptor Related Protein 1 8 0.31 25.8 0.0111
IL7 Interleukin 7 0.22 0.015 14.7 0.0012
IFI27 Interferon gamma-inducible protein 27 0.82 0.07 11.7 0.0006
OAS1 2′-5′-oligoadenylate synthetase 1 0.23 0.024 9.6 0.022
CHMP5 Charged multivesicular body protein 5 1.78 0.21 8.5 0.0728
IL6 Interleukin 6 26.57 3.93 6.8 0.0728
SPATS2L Spermatogenesis associated, serine-rich 2-like 2.12 0.317 6.7 0.0012
TLR4 Toll Like Receptor 4 0.88 0.16 5.5 0.011
NT5C3B 5′-nucleotidase cytosolic IIIB 0.37 0.07 5.3 0.0041
CCL8 Chemokine C-C motif ligand 8 0.12 0.023 5.2 0.0006
CXCL10 C-X-C motif chemokine 10 0.56 0.11 5.1 0.038
ABCA1 ATP Binding Cassette Subfamily A Member 1 2.88 0.59 4.9 0.0728
IFITM3 Interferon induced transmembrane protein 3 11.6 2.47 4.7 0.026
IFI35 Interferon alpha-inducible protein 35 1.29 0.28 4.6 0.0728
RTP4 Receptor (chemosensory) transporter protein 4 0.12 0.03 4 0.0728
PRKRA Protein Kinase, Interferon-Inducible DoubleStranded RNA Dependent Activator 0.83 0.21 4.0 0.073
GBP1 Guanylate binding protein 1 3.3 0.84 3.9 0.038
STING Stimulator of interferon genes 1.25 0.46 2.7 0.073
PLSCR1 Phospholipid scramblase 1 2.04 0.81 2.5 0.0262
IFI44L Interferon induced protein 44 like 0.35 0.16 2.2 0.0262
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Table 3. Cont.
Gene ID Gene Name MSC (Median) HLC (Median) Fold Difference p Value
IFIT5 Interferon induced protein with tetratricopeptiderepeats 5 0.26 0.12 2.2 0.0006
IFI16 Interferon inducible alpha protein 16 1.164 0.56 2.1 0.0041
IFNAR2 Interferon alpha receptor 2 1.36 0.66 2.1 0.035
IFNG Interferon gamma 0.003 1.29 430 0.0167
RGS1 Regulator of G protein signalling 1 0.18 21.98 122.1 0.0006
LAMP3 Lysosome associated membrane glycoprotein 3 0.02 0.48 24 0.0023
FCGR1B Fc fragment of IgG receptor IB 0.003 0.065 21.7 0.0513
IL7R Interleukin 7 receptor 0.19 2.89 15.2 0.0012
SIGLEC1 Sialic acid binding Ig like Lectin 1 0.008 0.08 10 0.0714
PRDM1 PR domain containing 1, with ZNF domain 0.71 3.6 5.1 0.011
LAIR1 Leukocyte associated immunoglobulin like receptor1 0.13 0.61 4.7 0.0023
TGFB PR domain containing 1, with ZNF domain 2.9 13.23 4.6 0.0012
ISG20 Interferon stimulated exonuclease gene 20kDa 1.17 5.081 4.3 0.0006
HPSE Heparanase 0.06 0.16 2.7 0.053
Top panel (PRDM10 to IFNAR2) includes ISGs that were expressed higher in MSCs over HLCs and the bottom
panel (IFNG to HPSE) includes the IRGs expressed higher in HLCs over MSCs in OA.
4. Discussion
This study investigated the IFN1 gene expression profile of human BM-MSCs in their native state
and upon culture and IFN1 stimulation. For the first time, it showed the expression of IFN1 receptors
and many ISGs in native uncultured human BM-MSCs, as well as dramatic changes in BM-MSC IFN1
receptor expression following standard culture and IFNα and IFNβ stimulation. This indicated an
ability of BM-MSCs to actively regulate their IFN1 receptor expression and autocrine IFN production
in response to exogenous IFN1s.
Previous pioneering work by James et al. has proposed the existence of two subpopulations
of BM-MSCs different in their IFN1 profiles as well as their differentiation, migratory
and immunoregulatory capacities (exemplified by clonal lines Y201 and Y202) [20]. However,
these immortalised cell lines were produced by virus-mediated telomerase gene transfer into
the cells, therefore a possibility of induced anti-viral IFN1 response in these BM-MSCs could
not be excluded. The current investigation has shown constitutive IFN1 signalling in uncultured
and nonvirally-transduced BM-MSCs from healthy donors, therefore revealing its homeostatic role
in health. It also independently confirmed a higher-level IFN1 pathway activity in Y202 cells compared
to Y201 cells, and, significantly, revealed a larger similarity of native BM-MSCs to Y201 cells rather
than Y202 cells. Such IFN1 gene expression profile indicated a moderate level of IFN1 pathway activity
in native human BM-MSCs.
In this study we compared native, uncultured BM-MSCs with a broad population of hematopoietic
lineage cells (BM-HLCs), similar to our previous publications [15,24]. We observed clear differences
in IFN1 profiles between BM-MSCs and BM-HLCs despite their residence in the same tissue environment.
Firstly, BM-MSCs expressed higher levels of IFN1 receptors, which might translate into their higher
responsiveness to minute amounts of IFN1s. Secondly, 17-fold higher expression of USP18 in BM-MSCs
than in BM-HLCs could indicate higher MSC responsiveness to IFNβ. This molecule has been recently
proposed to be a negative regulator of IFN1 signalling affecting cell viability and response to viral
infection at multiple levels [50,51], and “a prime candidate to explain differential activation via
IFNβ versus IFNα” [52]. The authors have also proposed that cell-specific, “tunable” IFN1 activities,
such antiproliferative and immunomodulatory activities, require high-affinity IFNβ binding and high
receptor densities. In the current study, we have demonstrated stronger antiproliferative effects of
IFNβ compared to IFNα on human BM-MSCs, in addition to showing their higher IFN1 receptor
transcript levels compared to BM-HLCs. This points towards a potentially prominent role of IFNβ
signalling in BM-MSC homeostasis. In agreement, another study has documented an important role
of IFNβ in the induction of BM-HSC niche-supporting phenotype in the BM-MSCs and a parallel
inhibition of their osteoblast differentiation [53].
As IFN1 responses have been also linked to stem cell aging and senescence, we explored
any differences in IFN1 profiles in native BM-MSCs and BM-HLCs in relation to donor age.
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While in BM-HLCs, several IFN1 ISGs were reduced in older donors, this was not observed in BM-MSCs.
In fact, while an antiaging gene KL was reduced in BM-HLCs in direct correlation with several ISGs,
this was not the case in BM-MSCs, in which KL correlated with a broader range of ISGs, suggesting a
possibility for an internal feedback mechanism of its regulation. It could be speculated that the higher
levels of STING in BM-MSCs reflect a potentially higher state of “readiness” for the recognition of
DDR-based cytosolic nucleic acids in BM-MSCs in comparison to BM-HLCs [47] that, consequently,
could explain no significant age-related differences in basal ROS intracellular levels in BM-MSCs.
Our functional experiments showing trends for positive relationships between STING and MTCH2
gene expression and basal ROS accumulation in uncultured BM-MSCs are encouraging and should
be validated in larger donor cohorts. These cytoplasmic nucleic acid sensing mechanisms may also
facilitate BM-MSC longevity, stemness and quiescence [17], which would be valuable to explore
in the future. Interestingly, the expression of two ISGs (SERPING1 and OAS2) has been recently
shown to be better maintained in three-dimensional (3D) BM-MSC culture compared to their 2D
culture [25]. Three-dimensional culture much better preserves the BM-MSC self-renewal ability,
the prime characteristic of “stemness” in different types of stem cells [54], suggesting that SERPING1,
also found to be highly BM-MSC-specific in the present study, could be an interesting candidate for
the study of BM-MSC self-renewal in vivo.
IFN1-tunable immunomodulatory function in vivo can be related to their control of osteoclast
formation [55,56] as well as lymphocyte development, maturation and memory cell retention [41],
with both processes known to be strongly affected by age. In the present study, we observed a
strong positive correlation between BM-MSC IL7 transcript expression, involved in both lymphocyte
development and memory cells retention in the BM, and the expression of several ISGs. IL7 transcription
in BM-MSCs can be controlled by regulatory factors activated by lymphocyte adhesion or extrinsic
IFNβ stimulation, and subsequently contribute to the myeloid skewing and inflamm-aging processes
in the elderly, as well as the progression of OA [57]. IL7 transcript showed a trend for downregulation
in BM-MSCs from OA patients in parallel with significant downregulation of several ISGs including
IFITM1, IFITM3 and USP18; this pointed towards potential involvement of IFN1 signalling pathway
in IL7 transcriptional regulation in OA. Remarkably, the expression of RANKL in BM-MSCs, a factor
inducing osteoclast differentiation and enhancing bone resorption [58], negatively correlated with
many analysed ISGs in the current study. This potentially implied a protective role of IFN1 signalling
in the BM-MSC control of bone resorption, which merits further investigations. Although we did
not observe particular correlations between ISG expression and classical bone formation transcripts
in native BM-MSCs, functional studies indicating a decline in osteoblasts [32] and the impairment
in extracellular matrix formation and mineralisation by IFN1 [53] indicate that further investigations are
needed to better understand the role of constitutive IFN1 signaling in the maintenance of bone strength.
This study is limited by low numbers of donors in younger and older age groups. However,
we uniquely used healthy BM donors and purified rare BM-MSCs using FACS sorting. Additionally,
a broader panel of genes, including genes involved in autophagy, as well as more ISGs and antiaging
genes, is needed to unravel the involvement of IFN1 signalling in BM-MSC survival and aging processes.
We were limited by the well-known low frequency of native BM-MSCs in BM aspirates [13,15], as well
as the volumes of aspirates that could be ethically sourced from human participants. This precluded
direct evaluation of the effects of IFN1 stimulation on uncultured BM-MSCs, which is additionally
compounded by low clonogenicity of sorted BM-MSCs [59], possibly due to cell stress induced by
cell sorting [60]. It is also unclear whether there is cell-to-cell heterogeneity within the sorted fraction
of native BM-MSCs. Indeed, different subpopulations of native BM-MSCs have been previously
described [61,62], some of which may indeed differ in their IFN1 signatures [20]. Novel methods
such as single-cell RNA sequencing [63] on larger cohorts of donors will be the next step forward for
addressing these questions. Furthermore, a proteomic analysis such as Western blot, enzyme-linked
immunosorbent assay (ELISA) or flow cytometric evaluation of critically important IFN1 genes
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in BM-MSCs would be required to have a greater view regarding the impact of IFNα and IFNβ
in BM-MSCs biology.
In summary, IFN1 responses in cells have been initially related to their antiviral activity, but more
recently, they have been linked to a broader range of “tonic” activities, including the control of cell
homeostasis, proliferation, immunomodulation, quiescence and senescence [45,64,65]. In this study,
we presented the homeostatic IFN1 profile of native human BM-MSCs and showed its difference
to hematopoietic, immune-lineage cells from the same BM microenvironment. Considering a large
proportion of selected IFN1 genes were overexpressed in BM-MSCs in comparison to BM-HLCs and,
in contrast, fewer age-related differences were found in BM-MSCs, BM-MSCs in vivo may uniquely
utilise IFN1 signalling machinery to resist aging influences compared to BM-resident immune-lineage
cells. This machinery may allow them to tolerate endogenous as well as exogenous ROS and, in turn,
help to prevent BM-HSC senescence [66]. The current work therefore opens new avenues for a broader
exploration of IFN1 signalling in native BM-MSCs towards its potential modulation for the prevention
of age-related inflamm-aging and bone frailty in the elderly.
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IFNα Interferon alpha
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HSCs Hematopoietic stem cells
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SIRT6 Sirtuin 6
ISGs Interferon stimulated genes
DNA Deoxyribonucleic acid
SSEA4 Stage specific embryonic antigen 4
cGAS/STING Cyclic GMP-AMP synthase/Stimulator of interferon genes
IFNAR1 Interferon alpha receptor 1
IFNAR2 Interferon alpha receptor 2
JAK Janus kinase
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STAT1 Signal transducer and activator of transcription1
Mx1 MX dynamine like GTPase 1
HERC5 HECT and RLD domain containing E3 ubiquitin protein ligase 5
IFTM1 Interferon induced trans membrane protein 1
IFITM3 Interferon induced trans membrane protein 3
IRF7 Interferon regulatory factor 7
RPT4 Receptor transporter protein 4
ISG20 Inteferon stimulated gene 20
BID BH3 interacting domain
MTCH2 Mitochondrial homologue carrier 2
ROS Reactive oxygen species
OA Osteoarthritis
OAS3 2′-5′-oligoadenylate synthetase 3
SASP Senescence associated secretory phenotype
IL6 Interleukin 6
IL8 Interleukin 8
USP18 Ubiquitin specific peptidase 18
FABP4 Fatty acid binding protein 4
PPARγ Peroxisome proliferator activator receptor gamma
RUNX2 Runt related transcription factor 2
SPARC Secreted protein acid and cysteine rich/Osteonectic
SOX9 SRY-Box Transcription Factor 9
ACAN Aggrecan
IL7 Interleukin 7
CXCL12 C-X-C chemokine 12
TNFSF11 Tumour necrosis factor super family 11
Ly6E Lymphocyte antigen 6E
EIF2AK2 Eukaryotic translation initiation factor 2-alpha kinase 2
TMEM173 Transmembrane protein 173/STING
IRF3 Interferon regulatory factor 3
CCND2 CyclinD2
IRF9 Interferon regulatory factor 9
IFI35 Interferon induced 35
RNF213 Ring finger protein 213
DDR DNA-damage response
3D Three dimensional
SERPING1 Serpin family G member1
EDTA Ethylene diamine tetra acetic acid
BMA Bone marrow aspirate
DMSO Dimethylsulfoxide
qPCR quantitative Polymerised chain reaction
IFC Integrated fluid circuits
DPBS Dulbeccos phosphate buffer saline
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